Delveinsight

JANUARY 5, 2021

Pfizer and OPKO Health: A step closer to FDA Nod for pediatric growth hormone deficiency (GHD) drug, Somatrogon. Pfizer and Opko had joined hands in 2014 to develop somatrogon , a pediatric growth hormone deficiency (GHD) drug. FDA Emergency Use Authorization for SCONE Medical’s Novel Aerosol Infection Containment Device.

Hormones 52

Hormones FDA Approval Trials Drugs 52

The Pharma Data

APRIL 13, 2022

Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) announced today an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 Food and Drug Administration, with a treatment duration of up to 24 months.

Drugs 52

Drugs Hormones Medicine Production 52

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. GLP-1 is a hormone that is produced naturally in the brain and the gut in response to food ingestion.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Drug Discovery World

APRIL 4, 2023

The Food and Drug Administration (FDA) in the US has made several key drug decisions over the last few weeks. The drug was granted orphan drug designation by the FDA in May 2021. The drug is expected to become a standard of care for these patients, who have had limited treatment options, according to analysts GlobalData.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /PRNewswire/ — RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company’s drug candidate, RV001. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers.

Drugs 40

Drugs Clinical Trials Clinical Trials Hormones 40

Trialfacts

NOVEMBER 23, 2022

Location: California Clinical Trials Medical Group 1560 East Chevy Chase Drive, Suite 140 Glendale, CA 91206. CNP is a hormone produced by the body that plays an important role in the bone growth of children. Researchers at Parexel want to understand how a new study drug, TransCon CNP behaves in the body. About the Study.

Clinical Trials 52

Clinical Trials Clinical Trials Hormones Research 52

XTalks

NOVEMBER 9, 2023

Eli Lilly is now fully armed on the GLP-1 front as it’s finally received US Food and Drug Administration (FDA) approval for Zepbound (tirzepatide), its obesity version of Mounjaro. Zepbound is Lilly’s answer to Novo’s blockbuster GLP-1 obesity drug Wegovy. The larger of the two trials enrolled adults without diabetes.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals. The DIAGNODE-2 Trial.

Vaccination 103

Vaccination Vaccine Insulin Trials 103

Trialfacts

MARCH 1, 2023

A placebo looks like the study treatment but does not contain the active components. Our key areas of focus are currently hormones, cognition, TMS. Marc Russo Genesis Research Services bring a range of clinical trial opportunities to our community, including world-first studies for pain management and healthy volunteer studies.

Research 52

Research Clinical Trials Clinical Trials Containment 52

Druggist

MAY 22, 2021

Gaviscon Advance and Double Action contain sodium alginate, which creates a ‘ hj ‘ in the stomach, preventing acid from escaping and therefore help to control symptoms of heartburn. Two main factors contribute to the presence of dyspepsia in the pregnancy: hormonal changes. acid reflux, nausea, or.

Containment 52

Containment Production Pharmacy Medicine 52

The Pharma Data

AUGUST 15, 2021

Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2?) The approval is based on results from the open-label Study 004 trial (N=61), where the major efficacy endpoint was overall response rate (ORR) in patients with VHL-associated RCC. WELIREG is the first HIF-2? of patients.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

Pfizer

JANUARY 27, 2023

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Sufficient information is not available to assess for a potential drug interaction. AUTHORIZED USE The U.S.

Marketing 75

Marketing Production Drugs Licensing 75

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

Druggist

FEBRUARY 28, 2021

Melatonin is a hormone that is released at night by the pineal gland located in the brain. Cochrane looked at a number of trials that involved airline passengers, airline staff and military personnel who used melatonin or placebo ( a dummy pill) to evaluate the effectiveness of melatonin. Melatonin liquid (Melatonin oral solution).

Pharmacy 98

Pharmacy Licensing Licensing Medicine 98

Pfizer

AUGUST 15, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Drugs listed in this section are a guide and not considered a comprehensive list of all drugs that may be contraindicated with PAXLOVID.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

AUGUST 17, 2021

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. across dMMR solid tumours 95% of responders had a duration of response of ?6

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. Drug Enforcement Administration. .” It was granted orphan drug designation for the treatment of narcolepsy in 2010. WAKIX is administered orally, once daily in the morning upon wakening.

FDA Approval 52

FDA Approval Hormones Production Drugs 52

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5

Insulin 98

Insulin Hormones FDA Approval Sales 98

Pfizer

DECEMBER 20, 2022

FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets).

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

MARCH 1, 2021

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? Prescription drugs used to treat dry eye are designed to dampen this inflammatory response and disrupt the cycle of severe dry eye disease.

Sales 119

Sales Drugs Life Science Containment 119

The Pharma Data

SEPTEMBER 16, 2020

Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating Gavreto TM (pralsetinib) for the treatment of people with RET-mutant medullary thyroid cancer. Food and Drug Administration, about four months earlier than anticipated, for the treatment of early and metastatic HER2-positive breast cancer.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

MARCH 25, 2021

Food and Drug Administration (FDA) to treat adult patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. About the ASCENT Study. Embryo-Fetal Toxicity.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

Camargo

NOVEMBER 29, 2021

Like with small molecules, clinical trials of biologics are designed to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and efficacy. Essentially, a biologic is a product that is produced from living organisms or that contains components of living organisms. Blood and blood components. Allergenics. Somatic cells.

Development 180

Development Protein Production Hormones 180

The Pharma Data

FEBRUARY 8, 2021

Metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer (mHSPC), refers to prostate cancer that still responds to hormonal therapy and has spread beyond the prostate to other parts of the body. [4]. 6] ERLEADA ® is being studied in five Phase 3 registrational clinical trials.

HR 52

HR Hormones Development Production 52

Pfizer

DECEMBER 13, 2022

In June of 2022, Pfizer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID for patients who are at high risk of progression to severe disease from COVID-19. The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in February 2023.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

APRIL 23, 2021

The ongoing phase 1 GARNET trial is evaluating dostarlimab as monotherapy in patients with advanced solid tumours. The collaboration has resulted in three monospecific antibody drugs that have progressed into the clinic. containing regimen. Hormone replacement therapy for endocrinopathies should be instituted as warranted.

Antibody 52

Antibody Hormones Licensing Licensing 52

XTalks

FEBRUARY 7, 2023

Current treatments for HR+ breast cancer patients include hormonal therapies, chemotherapies for those that do not respond to hormonal therapy alone and targeted therapies, either stand-alone or in combination with hormonal therapies. Trodelvy is a Targeted Therapy Trodelvy is a Trop -2 directed antibody-drug conjugate therapy.

HR 52

HR Hormones FDA Approval Antibody 52

Druggist

NOVEMBER 27, 2020

This year, clascoterone (brand name: Winlevi) has been approved by The United States Food and Drug Administration (FDA) for treatment of acne in the US. The approval decision for drug licensing comes from information gathered during clinical trials. At the end of the 12-week trial, the treatment was successful in 18.4%

Hormones 98

Hormones Containment Clinical Trials Clinical Trials 98

pharmaphorum

JULY 28, 2022

The American Heart Association issued a statement last year highlighting the risks of visceral and abdominal fat (VAT), calling for clinical trials of therapies to reduce it, as well as greater efforts to encourage patients to exercise and improve their diets. Image by Bruno /Germany from Pixabay .

Biobanking 52

Biobanking Gene Gene Silencing Drugs 52

The Pharma Data

APRIL 27, 2021

Today’s ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. About triple-negative breast cancer Breast cancer is the most common cancer among women with more than 2 million diagnosed worldwide each year.1

Medicine 40

Medicine In-Vitro Antibody Development 40

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase III drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FDA Approval 100

FDA Approval Containment Development Genome 100

Pfizer

JANUARY 27, 2023

In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus. AUTHORIZED USE The U.S.

Research 112

Research Vaccination Vaccine Drugs 112

XTalks

AUGUST 2, 2023

Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. Comirnaty was first approved by the US Food and Drug Administration (FDA) in August 2021 for individuals over the age of 16. It contains the antiviral medications nirmatrelvir and ritonavir.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pfizer

NOVEMBER 23, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Sufficient information is not available to assess for a potential drug interaction. Our Commitment to Access. AUTHORIZED USE. IMPORTANT SAFETY INFORMATION.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

MAY 9, 2022

Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for MYFEMBREE ® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 The extended Prescription Drug User Fee Act (PDUFA) goal date is August 6, 2022. “We Myovant Sciences (NYSE: MYOV) and Pfizer Inc.

Drugs 52

Drugs Hormones Medicine Containment 52

The Pharma Data

JUNE 2, 2022

Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 The FDA set a target action date of January 29, 2023 for this sNDA under the Prescription Drug User Fee Act (PDUFA).

Drugs 52

Drugs Hormones Development Medicine 52